Stem Memory T Cell Culture Using Mannose for Scalable Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing and expanding stem memory T cells in vitro are inefficient, costly, and pose safety risks, making them unsuitable for large-scale production and clinical applications.
Innovation Solution
A method involving the use of mannose in the culture medium during or after T cell activation, combined with cytokines like IL-2, IL-7, IL-15, and IL-21, to promote the expansion of stem memory T cells, utilizing antibodies such as CD3 and CD28 for activation and stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional culture conditions are used to expand T cells, then T cell proliferation occurs, but stem memory T cell induction efficiency is low
Solution Approach 1:
The patent changes the chemical composition parameters of the culture medium by adding mannose (2-20 mM) to conventional cytokine-containing media. This parameter modification transforms the culture environment to specifically promote stem memory T cell induction while maintaining T cell proliferation, thereby resolving the contradiction between induction efficiency and cell yield.
Solution Approach 2:
Mannose acts as an intermediary substance that mediates the differentiation process of T cells. It works synergistically with cytokines (IL-2, IL-7, IL-15, IL-21) to guide T cell fate toward stem memory phenotype, enabling efficient induction without compromising expansion capability.
2Productivity
If cytokines IL-7, IL-15 and IL-21 are used in large quantity to improve stem memory T cell induction, then induction ratio improves, but production cost increases greatly
Solution Approach 1:
The patent replaces expensive cytokine combinations with mannose, a cheap and readily available sugar. Mannose can be added in large quantities without significantly increasing production cost, while still achieving high stem memory T cell induction ratios when combined with minimal cytokine supplementation.
Solution Approach 2:
The patent modifies the cytokine concentration parameters to reduced levels while adding mannose, creating a cost-effective culture regimen that maintains high induction efficiency without requiring large quantities of expensive cytokines.
3Manufacturing precision
If flow cytometer sorting technology is used to obtain stem memory T cells, then pure stem memory T cell population is achieved, but the process is not suitable for large-scale production due to high instrument requirements and microbial infection risk
Solution Approach 1:
The patent replaces the mechanical flow cytometer sorting system with a biochemical culture method using mannose. This substitution eliminates the need for complex instrumentation and reduces microbial infection risks while maintaining the ability to generate high-purity stem memory T cell populations through selective induction.
Solution Approach 2:
The culture system allows stem memory T cells to self-select and self-amplify through mannose-mediated differential proliferation. The biochemical environment naturally favors stem memory T cell expansion without requiring external sorting operations, enabling scalable production.
4Speed
If terminal effector T cells are used for adoptive cell therapy, then immediate anti-tumor effect is achieved, but long-term survival in the body is difficult
Solution Approach 1:
The patent performs preliminary differentiation of T cells into stem memory phenotype before adoptive transfer. This preliminary action endows the cells with both immediate effector functionality and long-term memory characteristics, ensuring both rapid anti-tumor effect and sustained persistence in the patient's body.
Solution Approach 2:
The patent creates a composite T cell population with hybrid characteristics: stem cell-like self-renewal capacity combined with effector T cell anti-tumor functionality. This composite phenotype achieves both immediate therapeutic effect and long-term durability.
Data Source
Figure 1
Figure 2A
Figure 2B~2C
AI summary
A method for inducing and expanding a stem memory T cell in vitro. The method includes obtaining a large number of stem memory T cells by means of changing the culture condition of T cells. The prepared stem memory T cell has a multidirectional differentiation potential and is suitable for any clinical adoptive immunotherapy, including tumor and infection immunity, autoimmune diseases, etc.